- Study at Deakin
- Life at Deakin
- Industry and community
- About Deakin
A joint venture will provide a world-first short nanofibre manufacturing capability in Geelong.
A world first technology platform has received a Victorian Engineering Excellence Award.
Chemists develop a new range of cancer therapeutics.
Cracking the cartilage riddle, Deakin scientists synthetically mimic the body's most complex lubrication system.
A new process to separate blends of cotton-polyester material provides a major breakthrough for recycling textile and other waste.
A / Prof Mark Kirkland
+61 (3) 522 71089
This research is carried out through a partnership with local biotechnology company Cytomatrix, the Advanced Manufacturing CRC and the Victorian Centre for Advanced Materials Manufacturing (VCAMM).
We are addressing the major challenge in the field of haematopoietic stem cell (HSC) biology - developing systems that support HSC self-renewal and controlled differentiation in vitro.
Haematopoietic stem cells are the key to clinical treatments, such as HSC transplants used to treat leukaemia. Achieving HSC expansion in vitro, while retaining their multipotency is the key to attaining higher HSC transplant clinical success.
Current systems available for HSC expansion in vitro are unsuitable for these clinical applications. We are developing integrated bioreactors and 3D scaffolds with high biomimicry for HSC selection from umbilical cord blood and expansion in vitro.
These scaffolds will allow greater levels of control over cell fate, enable large volume processing and expansion of HSC and will be tailorable to other stem cell applications.
IFM is at the forefront of the development of a new class of nanomaterials known as short nanofibres. Our group research is focused on:
Deakin University CRICOS Provider Code: 00113B